Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.48 CAD | 0.00% | -4.00% | +62.71% |
Apr. 25 | NurExone Biologic Announces OTCQB Listing And DTC Eligibility | MT |
Apr. 02 | NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 12.25 | 10.75 | 23.11 | - | - |
Enterprise Value (EV) 1 | 12.25 | 10.75 | 23.11 | 23.11 | 23.11 |
P/E ratio | -1.32 x | -2.75 x | -3.9 x | -3.9 x | -7.02 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 42,855 | 48,250 | 65,830 | - | - |
Reference price 2 | 0.2858 | 0.2228 | 0.3511 | 0.3511 | 0.3511 |
Announcement Date | 3/30/23 | 4/2/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -3.657 | -4.75 | -4.75 | - |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -3.639 | -4.737 | -4.737 | - |
Net income 1 | -8.169 | -3.639 | -4.737 | -4.737 | - |
Net margin | - | - | - | - | - |
EPS 2 | -0.2160 | -0.0810 | -0.0900 | -0.0900 | -0.0500 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 3/30/23 | 4/2/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -1.06 | -1.164 | -0.716 | -1.05 | -1.1 | -1.2 | -1.4 | -1.05 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -1.04 | -1.158 | -0.737 | -1.035 | -1.101 | -1.201 | -1.401 | -1.035 |
Net income 1 | -1.04 | -1.158 | -0.737 | -1.035 | -1.101 | -1.201 | -1.401 | -1.035 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -0.0240 | -0.0260 | -0.0150 | -0.0200 | -0.0200 | -0.0200 | -0.0300 | -0.0200 |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 8/28/23 | 11/24/23 | 4/2/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 3/30/23 | 4/2/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.71% | 23.11M | |
+63.12% | 62.59B | |
-2.36% | 41.18B | |
+44.36% | 40.29B | |
-8.29% | 27.9B | |
+11.78% | 26.21B | |
-21.99% | 19.09B | |
+4.83% | 13.08B | |
+24.90% | 12.26B | |
+28.30% | 12.05B |
- Stock Market
- Equities
- NRX Stock
- Financials NurExone Biologic Inc.